Monitoring eosinophils to guide therapy with Biologics in Asthma: does the compartment matter?

Leo Koenderman, Marwan Hassani, Manali Mukherjee, Parameswaran Nair

Research output: Contribution to journalArticleAcademicpeer-review

10 Downloads (Pure)

Abstract

Eosinophils, since their initial description by Thomas Wharton Jones in 1846, and staining characteristics by Paul Ehrlich in 1879, have been associated with asthma1 . They are produced in the bone marrow, from pluripotential stem cells, whichfirst differentiate, largely regulated by a transcription factor GATA-1, into a hybrid precursor for both basophils and eosinophils, and then into a separate eosinophil lineage. The eosinophilopoietins IL-3, GM-CSF and notably IL-5 regulatetheir further expansion and migration out of the bonemarrow into the circulation.Circulating eosinophils subsequently interactwith the endothelium by processes involving rolling, adhesion, and diapedesis. Depending on the targetorgan, eosinophils cross the endothelium into tissues by a regulated process involving the coordinatedinteraction between networks involving cytokines such as IL-13, the chemokine eotaxin-1, eosinophil adhesion molecules (α4β1, α4β7, αmβ2, αLβ2), and adhesion receptors on the endothelium (MAdCAM-1, VCAM-1, and ICAM-1). Under homeostatic conditions, eosinophils traffic into the thymus, mammary gland, uterus, and most prominently into the gastrointestinal tract.

Original languageEnglish
Pages (from-to)1294-1297
Number of pages4
JournalAllergy
Volume76
Issue number4
Early online date31 Dec 2020
DOIs
Publication statusPublished - Apr 2021

Fingerprint

Dive into the research topics of 'Monitoring eosinophils to guide therapy with Biologics in Asthma: does the compartment matter?'. Together they form a unique fingerprint.

Cite this